MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 20, 2026
TickeronGET DAILY SIGNALS
Why Is Glass House Brands (GLAS) Stock Down -9.35% Today?

Why Is Glass House Brands (GLAS) Stock Down -9.35% Today?

Key Takeaways

  • GLAS shares fell roughly 9.35% to about $2.23, extending the prior session's sharp decline.
  • The selloff follows preliminary third-quarter results that showed a steep drop in average selling prices and compressed gross margins.
  • Lake Street lowered its price target on the stock to $7 from $17 while maintaining a Buy rating.
  • Concerns about equity dilution and a board resignation added to the negative sentiment.
  • Traders are watching the full Q3 filing, cost-per-pound progress, and the company's path to cash-flow positive.

Opening Summary

Glass House Brands Inc. (GLAS), a vertically integrated California-based cannabis company known for its Glass House Farms, PLUS, Allswell, and Mama Sue brands, saw its stock fall about 9.35% on Tuesday, slipping to roughly $2.23 from a prior close of $2.46. The decline extends a drop of nearly 23% in the previous session and reflects continued investor unease after the company's preliminary third-quarter results revealed significant pricing and margin pressure in the California cannabis market.

Preliminary Q3 Results Expose Pricing and Margin Pressure

The primary catalyst behind the extended selloff is the company's preliminary and unaudited third-quarter results. While GLAS reported record revenue of $56.8 million and record biomass production of roughly 317,000 pounds, the details underneath the headline numbers worried investors. Average selling price fell to approximately $150 per pound, down sharply from $211 per pound in the second quarter. As a result, gross profit of $14.9 million translated to a 26% margin, down from 34% in the prior quarter, and operating cash flow slipped to negative $0.4 million.

Management attributed the softer results to a trim-heavy sales mix and persistently challenging pricing in the California cannabis market. Although the company reaffirmed its full-year 2026 production guidance of roughly one million pounds and its long-term cost target of $95 per pound, the market focused on the margin deterioration rather than the operational milestones.

Analyst Reaction: Lake Street Slashes Price Target

The downward pressure intensified after Lake Street cut its price target on GLAS to $7 from $17, though it kept a Buy rating on the shares. The firm described the preliminary Q3 results as "mixed" and reduced its 2026 and 2027 adjusted EBITDA estimates to account for softer pricing, an unfavorable product mix, and a more gradual margin recovery. The magnitude of the target reduction underscored how quickly expectations around profitability have reset.

Dilution and Governance Overhang

Investors are also contending with the lingering effect of the company's at-the-market (ATM) equity program. During the third quarter, GLAS raised $18 million through the ATM at an average price of $8.11 per share, plus $10 million from warrants, bringing total 2026 ATM proceeds to about $46 million at an average of $8.41 per share. With the stock now trading near $2.23 — well below those issuance prices — concerns about dilution and the depressed share price have compounded the negative sentiment. Separately, the company announced the resignation of board member John Nichols Jr., adding an element of governance uncertainty to the mix.

Market Context and Trading Activity

Trading activity has been unusually heavy. Monday's session, when the preliminary results were absorbed, saw more than 16 million shares change hands — several times the stock's recent average daily volume. Tuesday's follow-through selling pushed the shares toward the lower end of their 52-week range, which spans roughly $1.67 to $13.93. The move diverged from broader equity indices, signaling that company-specific and sector-specific factors — particularly California wholesale cannabis pricing — were the dominant drivers rather than a broad market pullback.

What Comes Next for GLAS

Looking ahead, investors will focus on the company's full third-quarter financial statements and any additional detail on pricing trends and cost execution. Management expects fourth-quarter cost of production to remain in line with third-quarter levels, and the company's GACP certification could open export opportunities. Key risks include continued pricing competition in California, the pace of margin recovery, and the company's ability to reach cash-flow positive without further dilutive capital raises. The reduced analyst expectations following the target cut will also shape how the market interprets upcoming results.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to identify opportunities across thousands of tickers. While Tickeron offers hundreds of bots, only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a range of approaches to explore. Visit the Trending AI Robots page to discover which strategies are leading in today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GLAS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


GLAS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 19, 2026

GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where GLAS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for GLAS turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 31 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

The 50-day moving average for GLAS moved below the 200-day moving average on September 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for GLAS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.023) is normal, around the industry mean (11.138). P/E Ratio (-3.066) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (178.797).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.33B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -3%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was 9%. RGC experienced the highest price growth at 33%, while GLAS experienced the biggest fall at -37%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 16%. For the same stocks of the Industry, the average monthly volume growth was 25% and the average quarterly volume growth was -0%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 59
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
View a ticker or compare two or three
GLAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Industry
N/A
Address
3645 Long Beach Boulevard
Phone
+1 212 299-7670
Employees
428
Web
https://www.glasshousebrands.com